[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352978-105":59,"doc-detail-352978-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pleiotrophin-in-mammary-gland-development-and-breast-cancer-a-comprehensive-review-of-the-evidence","Pleiotrophin in Mammary Gland Development and Breast Cancer - A Comprehensive Review of the Evidence","","Pleiotrophin (PTN) is a heparin-binding growth factor with mitogenic and angiogenic functions that regulates mammary gland biology and may drive breast cancer progression. This review consolidates evidence spanning normal development—where PTN can delay ductal outgrowth—and triple negative breast cancer—where it promotes lung metastasis and associates with poor survival. Reported expression patterns show reduced PTN transcription in tumors versus normal cells, contrasted by elevated serum PTN protein levels. The article evaluates PTN expression and cellular functions, links PTN to tumor microenvironment interactions, and assesses preclinical models, clinical correlations, and emerging biomarker data. It also identifies substantial gaps in context-specific signaling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pleiotrophin-in-mammary-gland-development-and-breast-cancer-a-comprehensive-review-of-the-evidence/352978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pleiotrophin-in-mammary-gland-development-and-breast-cancer-a-comprehensive-review-of-the-evidence/352978.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does PTN signaling function in mammary tissue and the tumor microenvironment?","Question",{"text":113,"@type":114},"PTN signals in a paracrine manner, with RNA and protein often detected in different cell types across mammary and tumor microenvironments. Its functional role is context-dependent across developmental and cancer settings.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Is PTN oncogenic during normal mammary gland development?",{"text":118,"@type":114},"No. In normal mammary development, PTN is described as not oncogenic, but it becomes pro-tumorigenic in breast cancer, especially in aggressive subtypes.",{"name":120,"@type":111,"acceptedAnswer":121},"What relationship does PTN show with breast cancer prognosis and potential clinical use?",{"text":122,"@type":114},"Elevated PTN serum protein levels in breast cancer patients correlate with poor overall survival, supporting interest in PTN as a liquid biomarker. The review positions the PTN signaling axis as a therapeutic opportunity and a candidate prognostic indicator.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352978,1791129887,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nPleiotrophin in Mammary Gland Development and Breast Cancer: A Comprehensive Review of the Evidence  \nArianna S. Gholami 1, Ciara N. Walsh 2 and Jean McBryan 2, *  \nAcademic Editors: Stefania Belli, Daniela Esposito and Roberto Bianco  \nReceived: 24 March 2026  \nRevised: 11 May 2026  \nAccepted: 13 May 2026  \nPublished: 18 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Medicine, RCSI University of Medicine and Health Sciences, 123 St Stephen’s Green, D02 YN77 Dublin, Ireland  \n2 Department Surgery, RCSI University of Medicine and Health Sciences, Beaumont Hospital, D09 YD60 Dublin, Ireland  \n* [Correspondence: jeanmcbryan@rcsi.ie](Correspondence: jeanmcbryan@rcsi.ie); Tel.: +353-1-8093825  \nHighlights  \nWhat are the main findings?  \n• The growth factor PTN signals in a paracrine manner, with RNA and protein often detected in different cell types of the mammary and tumour microenvironments.  \n• PTN’s functional role is context-dependent; it is not oncogenic in normal mammary development but becomes pro-tumorigenic in breast cancer, with the strongest effects in aggressive subtypes.  \nWhat are the implications of the main findings?  \n• The PTN signalling axis represents a therapeutic opportunity, particularly in aggressive subtypes such as triple negative breast cancer and highlights the need for integrated tissue-stromal-circulating analysis in biomarker and drug-development efforts.  \nAbstract  \nPleiotrophin (PTN), a heparin-binding growth factor with potent mitogenic and angiogenic activity, has emerged as a key regulator of mammary gland biology and a potential driver of breast cancer progression. This review integrates current evidence on PTN’s roles from normal mammary development, where it can delay ductal outgrowth, to triple negative breast cancer, where it promotes lung metastasis and correlates with poor survival. Though frequently reported as being overexpressed in breast cancer, the published data indicates that PTN transcription is reduced in cancer relative to normal breast cells. By contrast, serum PTN protein levels have been shown by multiple studies to be elevated in breast cancer patients relative to healthy controls. We examine the expression and function of PTNat a cellular level and explore the interplay between PTN and the tumour microenvironment. We evaluate preclinical models, clinical correlations, and emerging biomarker data that position PTN as a candidate prognostic indicator and therapeutic target. Despite growing interest, significant gaps remain regarding context-specific signalling. By integrating developmental and oncogenic perspectives, this review highlights PTN as a pivotal but underexplored factor in mammary gland physiology and breast cancer and outlines future research directions needed to translate PTN-targeted strategies into clinical benefit.  \nKeywords: pleiotrophin; breast cancer; transcriptomics; serum; biomarker; drug resistance; angiogenesis; development  \n1. Introduction  \nThe growth factor pleiotrophin (PTN) has been implicated in diverse developmental and pathological processes, yet its specific relevance to breast cancer remains poorly defined. Although PTN has been studied for more than three decades, the literature on its role in mammary gland biology and tumour progression is fragmented, with inconsistent reportson its expression patterns and context-dependent signalling.  \nAs a secreted protein, PTN has recently been detected in serum of breast cancer patients, where elevated levels correlate with poor overall survival, raising interest in PTNas a potential liquid biomarker [1,2] . PTN has also been implicated in establishing a prometastatic niche and in reducing sensitivity to breast cancer therapies [3] . However, no unified framework currently integrates PTN’s developmental functions","cbCaibBx2urWycSE","https://ap.wps.com/l/cbCaibBx2urWycSE","pdf",3409043,22,"English","# Highlights\n## Main findings\n## Main implications\n# Abstract\n# 1. Introduction\n# 2. Background\n## Molecular identity and gene location\n## Historical classification and nomenclature\n## Expanded biological functions","[{\"question\":\"How does PTN signaling function in mammary tissue and the tumor microenvironment?\",\"answer\":\"PTN signals in a paracrine manner, with RNA and protein often detected in different cell types across mammary and tumor microenvironments. Its functional role is context-dependent across developmental and cancer settings.\"},{\"question\":\"Is PTN oncogenic during normal mammary gland development?\",\"answer\":\"No. In normal mammary development, PTN is described as not oncogenic, but it becomes pro-tumorigenic in breast cancer, especially in aggressive subtypes.\"},{\"question\":\"What relationship does PTN show with breast cancer prognosis and potential clinical use?\",\"answer\":\"Elevated PTN serum protein levels in breast cancer patients correlate with poor overall survival, supporting interest in PTN as a liquid biomarker. The review positions the PTN signaling axis as a therapeutic opportunity and a candidate prognostic indicator.\"}]","Pleiotrophin in Mammary Gland Development and Breast Cancer - A Comprehensive Review of the Evidence | PDF",1790102369,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3cbbfc203aa60198d22a7f38a281e5f.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63950c7051e2c2875d59f50315bf0afd.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5218223c5a5546a422e81a3e899624a3.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9456918481baa0e3a2094a754fff9e9a.webp",980,1385]